

JMJD6 Antibody (C-term) Blocking peptide

Synthetic peptide Catalog # BP14160b

Specification

JMJD6 Antibody (C-term) Blocking peptide - Product Information

Primary Accession

Q6NYC1

JMJD6 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 23210

Other Names

Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6, 11411-, Histone arginine demethylase JMJD6, JmjC domain-containing protein 6, Jumonji domain-containing protein 6, Lysyl-hydroxylase JMJD6, Peptide-lysine 5-dioxygenase JMJD6, Phosphatidylserine receptor, Protein PTDSR, JMJD6, KIAA0585, PTDSR

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP14160b was selected from the C-term region of JMJD6. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

JMJD6 Antibody (C-term) Blocking peptide - Protein Information

Name JMJD6 (HGNC:19355)

Function

Dioxygenase that can both act as a arginine demethylase and a lysyl-hydroxylase (PubMed:24498420, PubMed:17947579, PubMed:20684070, PubMed:21060799, PubMed:22189873, PubMed:22189873, Acts as a lysyl-hydroxylase that catalyzes 5-hydroxylation on specific lysine residues of target proteins such as U2AF2/U2AF65 and LUC7L2. Regulates RNA splicing by mediating 5-hydroxylation of U2AF2/U2AF65, affecting the pre-mRNA splicing activity of U2AF2/U2AF65 (PubMed:19574390/a>). Hydroxylates



Tel: 858.875.1900 Fax: 858.875.1999

its own N-terminus, which is required for homooligomerization (PubMed: 22189873). Plays a role in the regulation of nucleolar liquid-liquid phase separation (LLPS) by post-translationally modifying LIAT1 at its lysine-rich domain which inhibits LIAT1 nucleolar targeting (By similarity). In addition to peptidyl-lysine 5-dioxygenase activity, may act as an RNA hydroxylase, as suggested by its ability to bind single strand RNA (PubMed:20679243, PubMed:29176719). Also acts as an arginine demethylase which preferentially demethylates asymmetric dimethylation (PubMed:17947579, PubMed:24498420, PubMed: 24360279). Demethylates histone H3 at 'Arg-2' (H3R2me) and histone H4 at 'Arg-3' (H4R3me), including mono-, symmetric di- and asymmetric dimethylated forms, thereby playing a role in histone code (PubMed:17947579, PubMed:24360279). However, histone arginine demethylation may not constitute the primary activity in vivo (PubMed:17947579, PubMed:21060799, PubMed:22189873). In collaboration with BRD4, interacts with the positive transcription elongation factor b (P-TEFb) complex in its active form to regulate polymerase II promoter-proximal pause release for transcriptional activation of a large cohort of genes. On distal enhancers, so called anti-pause enhancers, demethylates both histone H4R3me2 and the methyl cap of 7SKsnRNA leading to the dismissal of the 75KsnRNA:HEXIM1 inhibitor complex. After removal of repressive marks, the complex BRD4:JMJD6 attract and retain the P-TEFb complex on chromatin, leading to its activation, promoter-proximal polymerase II pause release, and transcriptional activation (PubMed: 24360279). Demethylates other arginine methylated- proteins such as ESR1 (PubMed: 24498420). Has no histone lysine demethylase activity (PubMed:21060799). Required for differentiation of multiple organs during embryogenesis. Acts as a key regulator of hematopoietic differentiation: required for angiogenic sprouting by regulating the pre-mRNA splicing activity of U2AF2/U2AF65 (By similarity). Seems to be necessary for the regulation of macrophage cytokine responses (PubMed: 15622002).

Cellular Location

Nucleus, nucleoplasm. Nucleus, nucleolus. Cytoplasm. Note=Mainly found throughout the nucleoplasm outside of regions containing heterochromatic DNA, with some localization in nucleolus. During mitosis, excluded from the nucleus and reappears in the telophase of the cell cycle.

Tissue Location

Highly expressed in the heart, skeletal muscle and kidney. Expressed at moderate or low level in brain, placenta, lung, liver, pancreas, spleen, thymus, prostate, testis and ovary. Up- regulated in many patients with chronic pancreatitis. Expressed in nursing thymic epithelial cells.

JMJD6 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

JMJD6 Antibody (C-term) Blocking peptide - Images

JMJD6 Antibody (C-term) Blocking peptide - Background





Tel: 858.875.1900 Fax: 858.875.1999

This gene encodes a nuclear protein with a JmjC domain.JmjC domain-containing proteins are predicted to function asprotein hydroxylases or histone demethylases. This protein wasfirst identified as a putative phosphatidylserine receptor involvedin phagocytosis of apoptotic cells; however, subsequent studieshave indicated that it does not directly function in the clearanceof apoptotic cells, and questioned whether it is a truephosphatidylserine receptor. Multiple transcript variants encodingdifferent isoforms have been found for this gene. [provided byRefSeg].

JMJD6 Antibody (C-term) Blocking peptide - References

Hong, X., et al. Proc. Natl. Acad. Sci. U.S.A. 107(33):14568-14572(2010)Mantri, M., et al. J. Mol. Biol. 401(2):211-222(2010)Zakharova, L., et al. J. Cell. Physiol. 221(1):84-91(2009)Webby, C.J., et al. Science 325(5936):90-93(2009)Klose, R.J., et al. Nat. Rev. Genet. 7(9):715-727(2006)